Evidence map›Paper›PMID 42191679›Full record

ArticleNature communications2026

Discovery of a KLHL41 Ligand for Muscle Specific Protein Degradation.

Junhyeong Yim, Jaeseok Lee, Solbi Kim, Jieun Choi, Soyoung Yoon, Hana Cho, Sunbin Jung, GaYeon Yoo, Sanghee Lee, Hankum Park and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Junhyeong Yim *Department of Chemistry, Kangwon National University, Chuncheon, Republic of Korea.ORCID 0000-0001-6709-0926
Jaeseok Lee *Department of Chemistry, Kangwon National University, Chuncheon, Republic of Korea.ORCID 0000-0002-8591-6792
Solbi Kim *Department of Chemistry, Kangwon National University, Chuncheon, Republic of Korea.
Jieun Choi *Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.ORCID 0000-0003-0054-0982
Soyoung YoonDepartment of Dental Sciences, School of Dentistry, Seoul National University, Seoul, Republic of Korea.
Hana ChoDepartment of Dental Sciences, School of Dentistry, Seoul National University, Seoul, Republic of Korea.ORCID 0000-0002-3591-2013
Sunbin JungDepartment of Dental Sciences, School of Dentistry, Seoul National University, Seoul, Republic of Korea.
GaYeon YooMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Sanghee LeeMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.ORCID 0000-0002-7765-5916
Hankum ParkDepartment of Dental Sciences, School of Dentistry, Seoul National University, Seoul, Republic of Korea. hanpark@snu.ac.kr.ORCID 0000-0001-5795-3249
Juyong LeeDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea. nicole23@snu.ac.kr.
Jongmin ParkDepartment of Chemistry, Kangwon National University, Chuncheon, Republic of Korea. jpark@kangwon.ac.kr.ORCID 0000-0001-8338-9346

Funding

Ministry of Education (Ministry of Education of the Republic of Korea) 2019R1A6C1010006Ministry of Education (Ministry of Education of the Republic of Korea) 5120200513755Ministry of Education (Ministry of Education of the Republic of Korea) RS-2023-00301850Ministry of Education (Ministry of Education of the Republic of Korea) RS-2023-00301976Ministry of Science, ICT and Future Planning (MSIP) RS-2023-00220628National Research Foundation of Korea (NRF) 2023R1A2C1007899National Research Foundation of Korea (NRF) NRF-2022R1C1C1005080National Research Foundation of Korea (NRF) RS-2023-00250887National Research Foundation of Korea (NRF) RS-2023-00256320National Research Foundation of Korea (NRF) RS-2023-00271205Seoul National University 860-20250088
6 · The paper itself

Abstract

Despite the recent advancement of proteolysis-targeting chimera (PROTAC) development, they remain predominantly dependent on two E3 ligases, CRBN and VHL, which are ubiquitously expressed in all types of cells. Recently, efforts to discover tissue-specific E3 ligase ligands get attention as a promising strategy to enable tissue-specific protein degradation and avoid off-target tissue effects. Advancing this line of research, we discover a ligand of KLHL41, a muscle-specific E3 ligase, through virtual screening. Building on the KLHL41 ligand, we develop KBD-1, a muscle-specific BRD4-targeting PROTAC with micromolar activity. To enhance degradation efficiency, we employ a two-body kinetic strategy, resulting in the covalent PROTAC cKBD-1, which achieves sub-nanomolar activity. cKBD-1 demonstrates muscle-specific BRD4 degradation through KLHL41 recruitment both in vitro and in vivo. Moreover, the KLHL41 ligand enables AR-targeting PROTAC development, demonstrating its broad applicability. These findings highlight the potential of KLHL41 as a platform for tissue-specific protein degradation and its applicability in therapeutic development.

Indexed as

MusclesProteolysisUbiquitin-Protein LigasesAnimalsBromodomain Containing ProteinsCell Cycle ProteinsHEK293 CellsHumansLigandsMiceNuclear ProteinsProteolysis Targeting ChimeraTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsLigandsNuclear ProteinsProteolysis Targeting ChimeraTranscription FactorsUbiquitin-Protein Ligases

Identifiers

PMID42191679
PMCPMC13212581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.